Robert Allen Koeppe
#109,436
Most Influential Person Now
Robert Allen Koeppe's AcademicInfluence.com Rankings
Robert Allen Koeppecomputer-science Degrees
Computer Science
#4087
World Rank
#4303
Historical Rank
Computer Graphics
#87
World Rank
#90
Historical Rank
Database
#1323
World Rank
#1395
Historical Rank
Download Badge
Chemistry Computer Science
Why Is Robert Allen Koeppe Influential?
(Suggest an Edit or Addition)Robert Allen Koeppe's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands (2007) (1854)
- Spatial working memory in humans as revealed by PET (1993) (1189)
- COMT val158met Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor (2003) (1131)
- A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. (1995) (1009)
- Age Differences in the Frontal Lateralization of Verbal and Spatial Working Memory Revealed by PET (2000) (987)
- Dissociating verbal and spatial working memory using PET. (1996) (979)
- Regional Mu Opioid Receptor Regulation of Sensory and Affective Dimensions of Pain (2001) (796)
- Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors (2005) (761)
- Dissociation of Storage and Rehearsal in Verbal Working Memory: Evidence From Positron Emission Tomography (1996) (718)
- Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
- Verbal Working Memory Load Affects Regional Brain Activation as Measured by PET (1997) (689)
- Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. (2009) (632)
- Brain activation in PTSD in response to trauma-related stimuli (1999) (625)
- Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI (2011) (615)
- The Role of Parietal Cortex in Verbal Working Memory (1998) (587)
- Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. (2008) (582)
- Inhibition in verbal working memory revealed by brain activation. (1998) (564)
- The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET (2015) (536)
- Amyloid deposition, hypometabolism, and longitudinal cognitive decline (2012) (534)
- Spatial versus Object Working Memory: PET Investigations (1995) (531)
- FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. (2007) (523)
- Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. (2003) (513)
- Components of verbal working memory: evidence from neuroimaging. (1998) (509)
- Positron emission tomographic analysis of cerebral structures activated specifically by repetitive noxious heat stimuli. (1994) (506)
- The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core (2010) (491)
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (487)
- Comparison of human cerebral activation pattern during cutaneous warmth, heat pain, and deep cold pain. (1996) (476)
- Individual Differences in Reward Responding Explain Placebo-Induced Expectations and Effects (2007) (446)
- Relationships between biomarkers in aging and dementia (2009) (440)
- Anatomic standardization: linear scaling and nonlinear warping of functional brain images. (1994) (423)
- Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. (2003) (372)
- In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (1996) (369)
- History of falls in Parkinson disease is associated with reduced cholinergic activity (2009) (354)
- Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography (1991) (351)
- In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease (1999) (336)
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
- Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging (1996) (308)
- Pronociceptive and Antinociceptive Effects of Estradiol through Endogenous Opioid Neurotransmission in Women (2006) (305)
- μ-Opioid Receptor-Mediated Antinociceptive Responses Differ in Men and Women (2002) (305)
- Variations in the Human Pain Stress Experience Mediated by Ventral and Dorsal Basal Ganglia Dopamine Activity (2006) (292)
- Isolation of Specific Interference Processing in the Stroop Task: PET Activation Studies (1997) (285)
- Decreased striatal dopaminergic innervation in REM sleep behavior disorder (2000) (284)
- Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. (2006) (273)
- PET Evidence for an Amodal Verbal Working Memory System (1996) (271)
- Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (2009) (271)
- Automated detection of the intercommissural line for stereotactic localization of functional brain images. (1993) (271)
- Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease (2010) (267)
- A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (252)
- "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. (1993) (251)
- Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers (2003) (251)
- Age Differences in Behavior and PET Activation Reveal Differences in Interference Resolution in Verbal Working Memory (2000) (244)
- Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios (2015) (240)
- Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease (2006) (237)
- Response of the μ-opioid system to social rejection and acceptance (2013) (212)
- Neuropsychological deficits are correlated with frontal hypometabolism in positron emission tomography studies of older alcoholic patients. (1993) (206)
- Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease (2012) (204)
- Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology (2016) (201)
- Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021) (200)
- The neural basis of task-switching in working memory: effects of performance and aging. (2001) (197)
- In vivo cerebral metabolism and central benzodiazepine‐receptor binding in temporal lobe epilepsy (1993) (194)
- Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study (2011) (193)
- The Effect of Emotional Content on Visual Recognition Memory: A PET Activation Study (1998) (188)
- APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study (2013) (184)
- Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography (1990) (183)
- Reducing between scanner differences in multi-center PET studies (2009) (177)
- A functional anatomic study of emotion in schizophrenia (2002) (171)
- The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 (2015) (170)
- Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography (1988) (168)
- Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. (1997) (167)
- The effect of graded aversive stimuli on limbic and visual activation (2000) (164)
- PET Imaging of human gliomas with ligands for the peripheral benzodiazepine binding site (1989) (163)
- Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease (2005) (162)
- Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE (2015) (161)
- It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder (2015) (160)
- Performance Comparison of Parameter Estimation Techniques for the Quantitation of Local Cerebral Blood Flow by Dynamic Positron Computed Tomography (1985) (160)
- Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease (2008) (160)
- Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia (2012) (155)
- Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative (2010) (153)
- Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (2006) (151)
- Increased ventral striatal monoaminergic innervation in Tourette syndrome (2003) (149)
- Dysregulation of regional endogenous opioid function in borderline personality disorder. (2010) (148)
- Impaired default network functional connectivity in autosomal dominant Alzheimer disease (2013) (146)
- Characterizing Alzheimer's disease using a hypometabolic convergence index (2011) (145)
- Limbic Activation and Psychophysiologic Responses to Aversive Visual Stimuli: Interaction with Cognitive Task (2000) (144)
- Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions (1996) (141)
- APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern (2015) (138)
- The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) (2013) (137)
- mu-opioid receptor-mediated antinociceptive responses differ in men and women. (2002) (136)
- Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (136)
- Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. (2013) (136)
- Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex (2000) (133)
- REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA (2003) (133)
- In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. (1994) (130)
- Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (2015) (130)
- 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects (2010) (126)
- Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes (2010) (123)
- Validation of a polysomnographic score for REM sleep behavior disorder. (2005) (120)
- Buprenorphine-Induced Changes in Mu-Opioid Receptor Availability in Male Heroin-Dependent Volunteers: A Preliminary Study (2000) (119)
- Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. (1996) (119)
- Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region (2015) (118)
- Smoking Modulation of μ-Opioid and Dopamine D2 Receptor-Mediated Neurotransmission in Humans (2007) (116)
- Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil (1991) (114)
- Verbal Fluency and Positron Emission Tomographic Mapping of Regional Cerebral Glucose Metabolism (1992) (113)
- A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease (2021) (113)
- Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease (2008) (112)
- Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. (1999) (112)
- Alternative Approach to Single-Scan Estimation of Cerebral Glucose Metabolic Rate Using Glucose Analogs, with Particular Application to Ischemia (1984) (111)
- Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. (2015) (111)
- Regional cerebral blood flow responses to smoking in tobacco smokers after overnight abstinence. (2005) (111)
- Parametric in vivo imaging of benzodiazepine receptor distribution in human brain (1991) (110)
- Changes in medial cortical blood flow with a stimulus-response compatibility task (1994) (109)
- 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. (2005) (108)
- Functional connectivity in autosomal dominant and late-onset Alzheimer disease. (2014) (106)
- Positron emission tomographic studies of cerebral benzodiazepine‐receptor binding in chronic alcoholics (1996) (105)
- Kinetic Modeling of N-[11C]Methylpiperidin-4-yl Propionate: Alternatives for Analysis of an Irreversible Positron Emission Tomography Tracer for Measurement of Acetylcholinesterase Activity in Human Brain (1999) (104)
- In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5-18F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses (2014) (104)
- Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases (2012) (104)
- Kinetic Evaluation of [11C]Dihydrotetrabenazine by Dynamic PET: Measurement of Vesicular Monoamine Transporter (1996) (103)
- Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers (2000) (102)
- Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing (2005) (102)
- Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography (1988) (102)
- Altered Central μ-Opioid Receptor Binding After Psychological Trauma (2007) (101)
- Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy (1994) (100)
- Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. (2011) (99)
- Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (2006) (97)
- A comparison of classification methods for differentiating fronto‐temporal dementia from Alzheimer's disease using FDG‐PET imaging (2004) (97)
- The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data (2015) (97)
- In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography (1992) (96)
- Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
- PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. (2006) (96)
- Gait speed in Parkinson disease correlates with cholinergic degeneration (2013) (96)
- Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study (2014) (95)
- Regional cerebral blood flow and plasma nicotine after smoking tobacco cigarettes (2004) (95)
- Oxytocin Gene Polymorphisms Influence Human Dopaminergic Function in a Sex-Dependent Manner (2012) (94)
- Regional cerebral blood flow effects of nicotine in overnight abstinent smokers (2001) (93)
- Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral Indices (2007) (93)
- Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. (1995) (93)
- Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. (1993) (92)
- Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia (2012) (92)
- Cholinergic system changes of falls and freezing of gait in Parkinson's disease (2019) (92)
- Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy (2000) (92)
- Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. (1994) (91)
- Imaging the vesicular monoamine transporter. (2001) (91)
- Diabetes is associated with postural instability and gait difficulty in Parkinson disease. (2013) (90)
- High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. (2000) (89)
- Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA (2003) (88)
- Neurocognitive ageing of storage and executive processes (2001) (87)
- Visual evoked potentials and positron emission tomographic mapping of regional cerebral blood flow and cerebral metabolism: can the neuronal potential generators be visualized? (1982) (87)
- Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography (1997) (87)
- Examination of assumptions for local cerebral blood flow studies in PET. (1987) (85)
- μ-Opioid receptors and limbic responses to aversive emotional stimuli (2002) (84)
- Decreased striatal monoaminergic terminals in Huntington disease (2000) (84)
- Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders (2012) (83)
- Integrated and automated data analysis method for neuronal activation studies using O-15 water PET (1993) (82)
- PROTON COMPUTED TOMOGRAPHY OF HUMAN SPECIMENS (1982) (81)
- β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia (2013) (80)
- PET evidence for multiple strategies of categorization (2001) (79)
- Assessment of Extrastriatal Vesicular Monoamine Transporter Binding Site Density Using Stereoisomers of [11C]Dihydrotetrabenazine (1999) (77)
- Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. (1995) (77)
- Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography (2008) (76)
- Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. (2011) (76)
- Positron emission tomography measures of benzodiazepine receptors in Huntington's disease (1993) (76)
- Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease (2019) (75)
- Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects (2001) (75)
- Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
- Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers (2000) (73)
- Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. (2014) (73)
- Reduced γ-aminobutyric acidA-benzodiazepine binding sites in insular cortex of individuals with panic disorder (2007) (72)
- Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET (2001) (70)
- Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease (2014) (69)
- [11C]Tropanyl Benzilate—Binding to Muscarinic Cholinergic Receptors: Methodology and Kinetic Modeling Alternatives (1994) (69)
- Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
- [15O]H2O positron emission tomography determination of cerebral blood flow during balloon test occlusion of the internal carotid artery. (1994) (69)
- Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease (2004) (68)
- In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography (1993) (68)
- Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism. (1997) (67)
- Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies (2019) (66)
- Striatal presynaptic monoaminergic vesicles are not increased in Tourette’s syndrome (1999) (66)
- Speech disorders in olivopontocerebellar atrophy correlate with positron emission tomography findings (1988) (66)
- Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates. (2014) (65)
- Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing (2018) (63)
- Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]Dihydrotetrabenazine and positron emission tomography (1998) (62)
- Determination of regional cerebral blood flow in patients with cerebral infarction. Use of fluoromethane labeled with fluorine 18 and positron emission tomography. (1984) (62)
- Motor dysfunction in olivopontocerebellar atrophy is related to cerebral metabolic rate studied with positron emission tomography (1988) (60)
- In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses (2006) (59)
- Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans (2012) (59)
- In vivo imaging of the brain vesicular monoamine transporter. (1995) (59)
- Dual-[11C]Tracer Single-Acquisition Positron Emission Tomography Studies (2001) (58)
- Inhibition of Neutral Amino Acid Transport Across the Human Blood‐Brain Barrier by Phenylalanine (1995) (56)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
- Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography (1996) (55)
- Clinical markers for identifying cholinergic deficits in Parkinson's disease (2015) (54)
- Time‐course of change in [11C]carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge (2007) (54)
- Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies (2018) (53)
- Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease (2016) (53)
- Distribution of pulmonary blood flow and total lung water during partial liquid ventilation in acute lung injury. (1997) (53)
- Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
- In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. (1992) (52)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
- Alteration of corticothalamic perfusion ratios during a PTSD flashback (1996) (52)
- Neuropsychological changes in olivopontocerebellar atrophy. (1990) (52)
- Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort (2011) (52)
- In Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia (2000) (51)
- Cerebral glucose hypermetabolism in Friedreich's ataxia detected with positron emission tomography (1990) (51)
- Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. (2009) (50)
- A Relationship between Metabolism in Frontal Lobes and Cerebellum in Normal Subjects Studied with PET (1988) (50)
- A Continuous Flow Input Function Detector for H2 15O Blood Flow Studies in Positron Emission Tomography (1986) (50)
- Biodistribution, dosimetry, metabolism and monkey PET studies of [18F]GBR 13119. Imaging the dopamine uptake system in vivo. (1989) (49)
- Quantitation of Local Cerebral Blood Flow and Partition Coefficient without Arterial Sampling: Theory and Validation (1985) (49)
- Correlation of Neuropsychological Function With Cerebral Metabolic Rate in Subdivisions of the Frontal Lobes of Older Alcoholic Patients Measured With [18F]Fluorodeoxyglucose and Positron Emission Tomography (1995) (49)
- Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study (2011) (47)
- Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. (2011) (47)
- Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome (2009) (47)
- Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. (1996) (46)
- Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (46)
- Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. (1995) (45)
- In Vivo Quantification of Cerebral Muscarinic Receptors in Normal Human Aging Using Positron Emission Tomography and [11C]Tropanyl Benzilate (1996) (45)
- Structural and functional brain imaging in Friedreich's ataxia. (1994) (44)
- Radiolabeled Cholinesterase Substrates: In Vitro Methods for Determining Structure-Activity Relationships and Identification of a Positron Emission Tomography Radiopharmaceutical for In Vivo Measurement of Butyrylcholinesterase Activity (2001) (44)
- Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding (1998) (43)
- 4-[18F]Fluoro-m-hydroxyphenethylguanidine: a radiopharmaceutical for quantifying regional cardiac sympathetic nerve density with positron emission tomography. (2013) (43)
- Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography (1999) (43)
- Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2 alpha-tropanyl benzilate: a central muscarinic receptor imaging agent. (1992) (43)
- Tobacco smoking produces greater striatal dopamine release in G-allele carriers with mu opioid receptor A118G polymorphism (2012) (42)
- Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. (2007) (42)
- Use of [11C]Aminocyclohexanecarboxylate for the Measurement of Amino Acid Uptake and Distribution Volume in Human Brain (1990) (39)
- Association of plasma and cortical amyloid beta is modulated by APOE ε4 status (2014) (38)
- Regional vesicular acetylcholine transporter distribution in human brain: A [18F]fluoroethoxybenzovesamicol positron emission tomography study (2018) (38)
- Improving PET Receptor Binding Estimates from Logan Plots Using Principal Component Analysis (2008) (38)
- Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo (2017) (38)
- Altered central micro-opioid receptor binding after psychological trauma. (2007) (37)
- The significance of family history status in relation to neuropsychological test performance and cerebral glucose metabolism studied with positron emission tomography in older alcoholic patients. (1998) (36)
- Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. (1992) (36)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
- Large-scale genomics unveil polygenic architecture of human cortical surface area (2015) (34)
- Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET. (2012) (34)
- Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase. (2019) (34)
- Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography (1995) (33)
- Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease (2014) (33)
- Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy (2002) (32)
- Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV (2018) (32)
- Serotonin, β‐amyloid, and cognition in Parkinson disease (2018) (32)
- Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab (2019) (30)
- Absence of normal activation of the left anterior fusiform gyrus during naming in left temporal lobe epilepsy (1998) (30)
- The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study (2012) (30)
- μ-Opioid activation in the prefrontal cortex in migraine attacks – brief report I (2014) (29)
- Anxiety and cerebral cortical metabolism in normal persons (1990) (28)
- A comparison of cerebral blood flow and glucose metabolism in olivopontocerebellar atrophy using PET (1995) (28)
- Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
- Validation of consensus panel diagnosis in dementia. (2010) (28)
- Denicotinized versus average nicotine tobacco cigarette smoking differentially releases striatal dopamine. (2013) (27)
- Effects of disulfiram on positron emission tomography and neuropsychological studies in severe chronic alcoholism. (1996) (27)
- Cerebral metabolic activity in idiopathic dystonia studied with positron emission tomography. (1988) (27)
- Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach (2021) (27)
- Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis (2004) (27)
- Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. (2016) (27)
- Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy (1997) (27)
- Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer’s disease (2008) (26)
- PET study of greater visual activation in schizophrenia. (1997) (26)
- Educational attainment and motor burden in Parkinson's disease (2015) (26)
- Changes in Sensory-Cognitive Input: Effects on Cerebral Blood Flow (1990) (26)
- Arterial/venous plasma nicotine concentrations following nicotine nasal spray (1999) (26)
- Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau (2020) (26)
- Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
- Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Imaging Biomarkers (2010) (25)
- Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation (2016) (24)
- Instrumentation for positron emission tomography: tomographs and data processing and display systems. (1992) (23)
- Stereotaxic Summation Analysis of Human Cerebral Benzodiazepine Binding Maps (1996) (23)
- Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity. (2011) (22)
- 18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
- Signal Separation and Parameter Estimation in Noninvasive Dual-Tracer PET Scans using Reference-Region Approaches (2009) (21)
- Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system (2019) (21)
- Calf flow reserve with H(2)(15)O PET as a quantifiable index of lower extremity flow. (2003) (20)
- μ-Opioid activation in the midbrain during migraine allodynia – brief report II (2014) (20)
- Assessing Mild Cognitive Impairment with Amyloid and Dopamine Terminal Molecular Imaging (2013) (20)
- Quantification of Cardiac Sympathetic Nerve Density with N-11C-Guanyl-meta-Octopamine and Tracer Kinetic Analysis (2013) (19)
- Effect of Aspartame‐Derived Phenylalanine on Neutral Amino Acid Uptake in Human Brain: A Positron Emission Tomography Study (1991) (19)
- A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
- Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception (2016) (19)
- Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs. (2020) (19)
- KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease (2021) (19)
- Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment (2010) (18)
- Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease (2020) (18)
- [18F]Fluoro-Hydroxyphenethylguanidines: Efficient Synthesis and Comparison of Two Structural Isomers as Radiotracers of Cardiac Sympathetic Innervation. (2017) (18)
- Scintigraphic portrayal of beta receptors in the heart. (1991) (17)
- Temporally Overlapping Dual-Tracer PET Studies (1998) (17)
- Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status (2021) (16)
- Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. (2012) (16)
- The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology (2021) (16)
- First-in-Human Studies of [ 18 F] Fluorohydroxyphenethylguanidines (2018) (16)
- Rhinorrhea: A common nondopaminergic feature of Parkinson's disease (2011) (16)
- Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson’s disease (2021) (16)
- Data Extraction from Brain PET Images Using Three-Dimensional Stereotactic Surface Projections (1998) (15)
- Heterogeneity of cholinergic denervation in Parkinson disease (2012) (15)
- Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats. (2013) (15)
- First-in-Human Studies of [18F] Fluorohydroxyphenethylguanidines: Positron Emission Tomography Radiotracers for Quantifying Regional Cardiac Sympathetic Nerve Density (2018) (15)
- Gender differences in cholinergic and dopaminergic deficits in Parkinson disease (2013) (15)
- Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease (2018) (15)
- 3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache (2014) (15)
- Xenon Effects on CNS Control of Respiratory Rate and Tidal Volume — The Danger of Apnea (1985) (14)
- Evaluation of [18F]N-methyl-lansoprazole as a tau PET imaging agent in first-in-human studies. (2020) (14)
- An updated synthesis of [11 C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor. (2017) (14)
- Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration. (2015) (14)
- Instability of Localization of Cerebral Blood Flow Activation Foci with Parametric Maps (1993) (14)
- Neutron Computed Tomography (1981) (13)
- Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease. (2014) (13)
- Cognitive Control as a 5-HT1A-Based Domain That Is Disrupted in Major Depressive Disorder (2019) (13)
- Deuterium Kinetic Isotope Effect Studies of a Potential in Vivo Metabolic Trapping Agent for Monoamine Oxidase B. (2018) (13)
- Kinetic Evaluation of Positron-Emitting Muscarinic Receptor Ligands Employing Direct Intracarotid Injection (1996) (13)
- Sensitivity of [11C]N-methylpyrrolidinyl benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methods. (2004) (13)
- History of falls in Parkinson disease is associated with reduced cholinergic but not nigrostriatal dopaminergic activity (2009) (12)
- Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study (2021) (12)
- A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
- Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. (2010) (12)
- Global Cerebral Blood Flow Increase Reveals Focal Hypoperfusion in Schizophrenia (1999) (11)
- Mixing in the Human Carotid Artery during Carotid Drug Infusion Studied with PET (1989) (11)
- Modeling autosomal dominant Alzheimer's disease with machine learning (2021) (11)
- Evaluation of 18F-labeled acetylcholinesterase substrates as PET radiotracers. (2005) (11)
- The brain areas involved in the executive control of task switching as revealed by PET (1996) (10)
- µ-Opioid Activity in Chronic TMD Pain Is Associated with COMT Polymorphism (2019) (10)
- Erratum: Dissociating verbal and spatial working memory using PET (Cerebral Cortex (January/February 1996) 6:1 (11-20)) (1998) (10)
- Constrained Least Squares Projection Filtering: A New Technique for the Reconstruction of Emission Computed Tomographic Images (1987) (10)
- Covariance of kinetic parameter estimators based on time activity curve reconstructions: preliminary study on 1D dynamic imaging (2004) (10)
- Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease (2021) (10)
- Equilibrium analysis of [11C]PIB studies (2008) (10)
- Selection of weighting factors for quantification of PET radioligand binding using simplified reference tissue models with noisy input functions (2012) (9)
- Post‐Mortem evaluation of amyloid‐dopamine terminal positron emission tomography dementia classifications (2015) (9)
- FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
- Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2. (2018) (9)
- Normal Striatal Vesicular Acetylcholine Transporter Expression in Tourette Syndrome (2017) (9)
- Regional Cerebral Blood Flow Measurement with Fluoromethane and Positron Tomography (1983) (9)
- Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease (2022) (9)
- Social feedback activates the endogenous opioid system (2013) (9)
- Postmenopausal hormone treatment alters neural pathways but does not improve verbal cognitive function (2018) (9)
- Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC) (2020) (9)
- The Centiloid Scale: Standardization of amyloid imaging measures (2013) (9)
- A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease (2020) (8)
- Strategies for PET imaging of the receptor for advanced glycation endproducts (RAGE) (2020) (8)
- Interpretation of metabolic abnormalities in Alzheimer's disease using three-dimensional stereotactic surface projections (3D-SSP) and normal database (1995) (7)
- Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
- α4β2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait–Balance Disorders (2020) (7)
- First-in-human studies of 18F-hydroxyphenethylguanidines: PET radiotracers for quantifying cardiac sympathetic nerve density. (2016) (7)
- PET imaging of the vesicular acetylcholine transporter (2012) (7)
- Baseline FDG-PET and volumetric MRI predicts Alzheimer's disease conversion from mild cognitive impairment: An ADNI study (2013) (6)
- TAU PET IMAGING WITH AV-1451 IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: UPDATE FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) (2016) (6)
- Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
- Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference (2018) (6)
- rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data (2021) (6)
- Normal Dopaminergic Nigrostriatal Innervation in SPG3A Hereditary Spastic Paraplegia (2008) (6)
- P3-070 Adding FDG-PET to clinical history and examination improves the accuracy of dementia diagnosis (2004) (6)
- Hypercapnia and cerebral blood flow: An approach to testing perfusion reserve (1984) (6)
- Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (6)
- Reduction of presynaptic monoaminergic vesicles in the striata of parkinsonian patients and in normal human aging. (1995) (6)
- Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease (2022) (6)
- Evaluation of methoxytetrabenazine as an in vivo tracer of monoamine nerve terminal integrity. (1994) (6)
- O1-02-06: Twelve-month cerebral metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer's disease neuroimaging initiative (ADNI) (2008) (6)
- Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (6)
- Copper-Mediated Radiocyanation of Unprotected Amino Acids and Peptides. (2022) (5)
- A positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients. (2003) (5)
- Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study (2022) (5)
- Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography. (1996) (5)
- Methodologic Considerations in Neuropsychologic Testing of Ataxic Patients-Reply (1992) (5)
- An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
- Radiosynthesis and comparisons in the biodistribution of carbon‐11 labeled muscarinic antagonists: (+)2α‐tropanyl benzilate and N‐methyl‐4‐piperidyl benzilate (1989) (5)
- Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center (2018) (5)
- Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1. (2018) (5)
- Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson’s disease: correlation with postural and gait deficits (2022) (4)
- Whole Brain Atrophy and Sample Size Estimate via Iterative Principal Component Analysis for Twelve-month Alzheimer's Disease Trials (2013) (4)
- Epilepsy surgery improves regional glucose metabolism on PET scan (1987) (4)
- A six-year longitudinal PET study of (+)-[11C]DTBZ binding to the VMAT2 in monkey brain. (2017) (4)
- Quantifying cardiac sympathetic denervation: first studies of 18F-fluorohydroxyphenethylguanidines in cardiomyopathy patients (2021) (4)
- Erratum: Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers (Psychopharmacology (2006) 185 (327-338) DOI: http//dx.doi.org/10.1007/s00213-006-0330-6) (2006) (4)
- The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus Monkeys (2020) (4)
- Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status. (2014) (4)
- [Integrated and automated data analysis for neuronal activation studies using positron emission tomography: methodology and applications]. (1994) (4)
- 240. Pet measures of monoaminergic synaptic density in bipolar I disorder: Relationship with age of onset (1998) (4)
- Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab (2020) (4)
- Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD (2020) (4)
- Decreased striatal monoaminergic presynaptic terminals in OPCA and MSA demonstrated with [11C]dihydrotetrabenazine and PET. (1995) (4)
- Olivopontocerebellar Atrophy Studied with Positron Emission Tomography (1988) (3)
- Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET. (2016) (3)
- Successful [18F]FEOBV imaging of the VAChT in monkey brain (2008) (3)
- PET Amyloid Analyses (2016) (3)
- Kinetic evaluation of [C-11]dihydrotetrabenazine (DTBZ) by dynamic PET : a marker for the vesicular monoamine transporter. (1995) (3)
- Quantification of amyloid beta and tau PET without a structural MRI (2022) (3)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
- Surface projection maps of cortical amyloid binding reveal canonical patterns in neurodegenerative dementias (2012) (3)
- Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
- Neuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRI (2022) (3)
- APOE effect on Alzheimer’s biomarkers in older adults with significant memory concern (2015) (3)
- Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (3)
- Effects of yohimbine on cerebral blood flow in humans: a pet study (1994) (2)
- Sex‐associated differences in pathology burden in early‐onset Alzheimer’s disease (2020) (2)
- Progression of regional cortical cholinergic denervation in Parkinson disease: a longitudinal acetycholinesterase 11C-PMP PET study (2018) (2)
- Respiratory motion gated PET with end-expiratory, amplitude based gating (2009) (2)
- Imaging butyrylcholinesterase activity in Alzheimer's disease (2006) (2)
- [Fast and accurate numerical method for principal components analysis dealing with large image data sets]. (1996) (2)
- Clinical correlation of multivariate spatial covariance analysis of 18F-FEOBV VAChT PET in Parkinson disease (2016) (2)
- Self- versus informant-based cognitive complaints: Relation of E-Cog scores to imaging, biomarkers and clinical Status in ADNI-2 (2013) (2)
- Gait Speed Is Preserved in Oligosystem Compared to Multisystem Neurodegeneration in Parkinson Disease (P04.165) (2013) (2)
- Impaired color perception is associated with more severe nigrostriatal denervation in Parkinson disease (2013) (2)
- metabolism in Normal (1990) (2)
- Imaging VMAT2 in Parkinson disease with [F-18]AV-133 (2008) (2)
- Gantenerumab in‐depth outcomes (2020) (2)
- Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
- Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication (2015) (2)
- Apathy but not depression is associated with amyloidopathy in Parkinson disease at risk for dementia (2015) (2)
- Psychological Factors and Pet Measured Glucose Metabolism in Olivopontocerebellar Atrophy (1996) (2)
- Progression of regional cortical cholinergic denervation in Parkinson's disease. (2022) (2)
- Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease (2022) (2)
- U.S. POINTER Imaging: Study design and launch (2020) (2)
- Interpretation of Regional Neurochemical and Anatomic Changes in Neurodegeneration: Multivariate Approach (1998) (2)
- Classics in Neuroimaging: Imaging the Cholinergic System with Positron Emission Tomography. (2021) (2)
- CHAPTER 39 – One for All or One for Each? Matching Radiotracers and Regional Brain Pharmacokinetics1 (1998) (1)
- Comparing Fludeoxyglucose F 18 – PET Assessment of Regional Cerebral Glucose Metabolism and [ 11 C ] Dihydrotetrabenazine – PET in Evaluation of Early Dementia and Mild Cognitive Impairment (2010) (1)
- Heritability of regional brain volumes in large-scale neuroimaging and genetic studies (2017) (1)
- Solanezumab in‐depth outcomes (2020) (1)
- PET measurement of glucose membrane transport using labeled analogs: Distinction of transport from metabolic processes (1984) (1)
- 350. Cortical and subcortical activation in response to emotional probes (2000) (1)
- 40. Viewing emotional stimuli increases skin conductance and blood flow in limbic brain (1998) (1)
- Improvement of an oxygen filtered neutron beam of 2.35 MeV (1979) (1)
- Odor identification is a more robust measure of forebrain cholinergic activity than odor memory/discrimination tests in Parkinson disease (2013) (1)
- Cerebellar acetylcholinesterase activity and parkinsonian motor impairment (2008) (1)
- Signal separation and parameter estimation in non-invasive dual-tracer PET (2008) (1)
- P-024 The pattern and severity of FDG pet abnormalities in Alzheimer’s disease and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer’s disease neuroimaging initiative (2007) (1)
- In vitro and in vivo binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is strereospecific. (1995) (1)
- Comorbid cortical {beta}-amyloid plaques affect postural instability and gait disorder symptoms in Parkinson disease (2012) (1)
- Optimizing quantification of MK6240 tau PET in unimpaired older adults (2022) (1)
- Importance of correction for intravascular radioactivity in dynamic PCT studies using glucose analogs (1985) (1)
- PET cardiac sympathetic imaging with 11C-hydroxyephedrine in idiopathic Parkinson's disease (2011) (1)
- PET Imaging of (2 R ,3 R )-5-[ 18 F]Fluoroethoxybenzovesamicol ((-)-FEOBV) in rat and monkey brain: A Radioligand for the Vesicular Acetylcholine Transporter (2009) (1)
- Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2021) (1)
- P1-258: Pinpointing change in Alzheimer's disease: Longitudinal FDG-PET analyses from the Alzheimer's disease neuroimaging initiative (2008) (1)
- Selective opiate modulation of pain processing in humans (1997) (1)
- Activation to salient emotional stimuli in the sublenticular zone and occipital cortex (2000) (1)
- Self-reported versus informant-based cognitive complaints: Relation of E-Cog scores to imaging biomarkers and clinical status in ADNI-2 (2013) (1)
- Ratings of activities of daily living are associated with cortical cholinergic but not with the degree of nigrostriatal dopaminergic activity in Parkinson disease (2009) (1)
- TWO-YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI-2 PARTICIPANTS: RELATION TO GENETIC RISK (2014) (1)
- Kinetic evaluation of [C-11] dihydrotetrabenazine : a PET ligand for assessing the vesicular monoamine transporter. (1995) (1)
- Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study (2012) (1)
- An accurate and computationally efficient method for voxel-by-voxel estimation of the Pittsburgh compound B distribution volume ratio (2008) (1)
- PIB PET 3-site stability study (2007) (1)
- Roles of COMT, NPY and GCH1 in acute and chronic pain/stress response (2014) (1)
- A pet activation study of selective attending during a stroop task (1994) (1)
- IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID-MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION-OF-INTEREST (2014) (1)
- Preparation of Fluorine-18 Deoxyfluorohexoses for Metabolism and Transport Studies (1988) (1)
- Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors. (2022) (1)
- 421. Symptoms associated with amygdaloid activity in schizophrenia (2000) (1)
- Amyloid and tau PET in sporadic early‐onset Alzheimer’s disease: Preliminary results from LEADS (2020) (1)
- Rapid calculation of functional maps of glucose metabolic rate and individual model rate parameters from serial 2-FDG images (1985) (1)
- MAO-B Inhibitor Deprenyl Displaces [18F]AV1451 binding on human brain tissue sections and alters uptake in Nonhuman Primate Brain (2019) (1)
- Strategies for the Production of [11C]LY2795050 for Clinical Use. (2023) (1)
- Reply from the Authors (1996) (1)
- P3-065 FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous (2004) (1)
- Signal separation in dual-tracer brain PET imaging using reference region models (2007) (1)
- Selective hyposmia and striatal monoaminergic vesicular binding binding in Parkinson disease (2008) (0)
- Choice of Inversion Time for Arterial Spin Labeling MRI in the U.S. POINTER Lifestyle Intervention Trial (2022) (0)
- Association between the Alzheimer's disease–related hypometabolic convergence index and clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer's Disease Neuroimaging Initiative (2013) (0)
- Differential modulation of visual cortex to complex visual stimuli in schizophrenic patients (1999) (0)
- IC-P2-098: Frequency of hemispheric metabolic asymmetry in probable Alzheimer's disease (2008) (0)
- Accounting for input function noise in weighting of residuals improves the performance of the simplified reference tissue model (2009) (0)
- Evaluation of Extrastriatal Specific Binding of [11C]Dihydrotetrabenazine Using Active and Inactive Enantiomers (2001) (0)
- Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence (2015) (0)
- Distinction between cerebral blood flow and vascular activity by PET tracer kinetic analysis: practical and physiologic considerations. (2001) (0)
- Diabetes Is Associated with Increased Central Neurotoxicity in Parkinson Disease: A Case-Control Study (P06.098) (2013) (0)
- Early frame of PiB and FDG in autosomal dominant Alzheimer's disease: Similarity, discrepancy, and clinical implication (2015) (0)
- Association between the Alzheimer's disease-related hypometabolic convergence index and clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer's Disease Neuroimaging Initiative (2013) (0)
- Use of an fdg-pet-derived hypometabolic convergence index enrichment strategy to reduce sample sizes in alzheimer's disease clinical trials: Findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (2011) (0)
- Use of Iterative Principal Component Analysis Based Whole Brain Atrophy to Detect Twelve-month Change in Alzheimer's Disease in Multi-center Trials: Findings from the Alzheimer's Disease Neuroimaging Initiative (2013) (0)
- Zubieta Responses to a Pain Stressor Genotype Affects μ-Opioid Neurotransmitter met 158 val COMT (2014) (0)
- Quantitative Functional Imaging Using Dynamic Positron Computed Tomography and Rapid Parameter Estimation Techniques (1984) (0)
- Qingxian Lu , Receptor Tyrosine Kinases of the Tyro 3 Family Homeostatic Regulation of the Immune System (2008) (0)
- Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family (0)
- in Normal &ng, AlzheimJs Disease, and Parlunson's Disease (1996) (0)
- Striatal vesicular acetylcholine transporter expression and cognitive function in Parkinson disease (2014) (0)
- Anxiety in Late Life Depression: Associations with Brain Structure and Functional Impairment (2023) (0)
- The pattern of cerebral hypometabolism and its association with clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer's Disease Neuroimaging Initiative (2013) (0)
- COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
- Use of an Alzheimer's Disease-Related Hypometabolic Convergence Index to Predict Progression from Mild Cognitive Impairment to Alzheimer's Dementia (2010) (0)
- IC-P1-036: Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's disease neuroimaging initiative (2008) (0)
- AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. (2022) (0)
- In vivo assessment of multiple neurodegenerations and cognitive impairment in Parkinson disease (2014) (0)
- Cardiovascular risk factors associate with cholinergic denervation in Parkinson disease (P2.152) (2015) (0)
- Cognitive, neuropsychiatric and imaging comparisons between early‐onset and late‐onset Alzheimer’s disease participants from LEADS and ADNI3 (2021) (0)
- IC-P-029 Quality assurance in a multi-center PET imaging trial (2006) (0)
- Use of an FDG-PET derived hypometabolic convergence index enrichment strategy to reduce sample sizes in Alzheimer's disease clinical trials: findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (2011) (0)
- Exploring Multimodal Ocular Imaging for Retinal Biomarkers of Alzheimer’s Disease, Frontotemporal Dementia, and Cognitively Normal Subjects (2021) (0)
- APOE e4 status modulates the association of plasma and cortical Aβ: Relation of plasma Aβ and [11C]PiB PET in the ADNI cohort (2011) (0)
- P1-244: Frequency of hemispheric metabolic asymmetry in probable Alzheimer's disease (2008) (0)
- Cross‐sectional amyloid and tau PET in cognitively normal older adults enrolled in the U.S. POINTER lifestyle intervention trial (2021) (0)
- Gender Differences in Dopaminergic and Cholinergic Integrity in Parkinson Disease (P06.080) (2013) (0)
- UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE POPULATION: REPORT FROM THE DIAN STUDY (2017) (0)
- IC-P2-074: Differentiating amnestic MCI converting to probable AD from stable amnestic MCI using FDG-PET and an AD-related hypometabolism overlap index (2008) (0)
- Temporoparietal hypometabolism is common in FTLD and is associated with imaging diagnostic errors (2011) (0)
- Capitalizing on complementary FDG PET and florbetapir PET data sets to distinguish between early and late mild cognitive impairment using multi-modal partial least squares (2012) (0)
- Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2022) (0)
- IC-P2-086: The pattern of cerebral hypometablism in amnestic mild cognitive impairment and its relationship to subsequent conversion to probable Alzheimer's disease: Preliminary findings from the Alzheimer's disease neuroimaging initiative (2008) (0)
- Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
- Differential cholinergic systems’ changes in progressive supranuclear palsy versus Parkinson’s disease: an exploratory analysis (2022) (0)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
- Processing complex visual information modulates limbic and occipital responses to emotionally salient stimuli (1999) (0)
- Development of Positron Emission Tomography (PET) Radiotracers for the GABA Transporter 1 (GAT-1) (2018) (0)
- Thalamic GABAa Receptor Expression is Inversely Correlated with Axial Motor Impairments in Parkinson Disease (P6.082) (2015) (0)
- 1-12-26 Striatal monoaminergic presynaptic terminals in Alzheimer's disease studied with (+)[11C]dihydrotetrabenazine and positron emission tomography (1997) (0)
- Mu-opioid receptors and rCBF response in the amygdala (2000) (0)
- "A Positron-emitting internal marker for identification of normal tissue by positron emission tomography: Phantom studies and validation in Patients," (Molecular Imaging and Biology (2003) vol. 5 (2) 79-85)) (2003) (0)
- INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS (2014) (0)
- Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology (2022) (0)
- Whole brain MRI‐free tau and amyloid PET quantification (2022) (0)
- Cholinergic system correlates of postural control changes in Parkinson's disease freezers. (2023) (0)
- A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
- alpha4beta2* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease (2020) (0)
- Metabolism of 11C-phenethylguanidines (2008) (0)
- Mode of head motion and its quantitative effect in 18F-FDG PET scans in the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multi-center study (2012) (0)
- Cross-sectional cerebral volumetric differences and associations with estimated time to age-at-onset in familial Alzheimer's disease: Findings from the DIAN study (2012) (0)
- Wide-spread CBF changes in cognitive tasks (1996) (0)
- Sex and APOE‐ε4 carrier effects on early‐onset Alzheimer’s disease pathology (2022) (0)
- Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach (2021) (0)
- EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2017) (0)
- Increased frontal lobe white matter lesion burden is associated with increased cortical and raphe nucleus serotonin transporter expression in normal elderly (2012) (0)
- Peduncolopontine nucleus-thalamic acetylcholinesterase activity in Alzheimer and Parkinson disease (2011) (0)
- P3-440 COMPARINGTHECENTILOID SCALEFOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
- Patlak slope of 11C-guanyl-meta-octopamine kinetics in nonhuman primates tracks reductions in cardiac norepinephrine transporter densities (2012) (0)
- FDG metabolism in the DIAN study of autosomal dominant Alzheimer's disease (2012) (0)
- Noninvasive alternatives to arterial blood sampling in positron emission tomography (1984) (0)
- Examining the effects of sex and age on tau PET binding in the absence of beta‐amyloid pathology (2022) (0)
- Both cortical cholinergic denervation and cortical {beta}-amyloid plaques contribute to cognitive impairment in Parkinson disease (2012) (0)
- INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS (2014) (0)
- Follow-up of the first American report of familial Alzheimer's disease (2012) (0)
- Amyloid load increase and cerebral microbleed prevalence differ as a function of the position of the mutation within the PSEN1 coding sequence (2015) (0)
- Quantitative analysis of 6,150 real‐world amyloid Positron Emission Tomography (PET) scans from the Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) study (2022) (0)
- Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
- Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study (2012) (0)
- Differentiation of Lewy body dementia from Parkinson's disease with [C-11]DTBZ PET (2005) (0)
- Society for Neuroscience 27th Annual Meeting, 25-30 October 1997, New Orleans, LA, USA (1997) (0)
- Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2020) (0)
- Effects of Scatter and Resolution on Regional Parametric Estimates from a Dual Tracer Study (1998) (0)
- Associations Between Elements of Recent Life Stress and Dopaminergic System Activity: a[11C] Raclopride Study (2009) (0)
- Capitalizing on complementary FDG-PET and florbetapir-PET data sets to distinguish between early and late mild cognitive impairment using multimodal partial least squares (2012) (0)
- Shape analysis method can be used for limited non-invasive estimation of striatal and cerebellar [11C]-PMP k3 hydrolysis rates (2011) (0)
- Donald M. Wieland, Ph.D. (2015) (0)
- Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration (2022) (0)
- Reply (0)
- Dopaminergic and cholinergic correlates of rhythmic foot oscillation control in Parkinson disease (2010) (0)
- Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
- Reply (2004) (0)
- Dopaminergic and Cholinergic Brain Activity and Performance on MMSE and MoCA in Parkinson's Disease (P03.127) (2012) (0)
- Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
- Postural sensory efficacy and striatal dopaminergic innervation in normal older adults (2010) (0)
- In Vivo Imaging of Benzodiazepine Receptors with Positron Emission Tomography (2020) (0)
- Regional covariance of brain cholinergic terminal changes in Parkinson disease: an 18F-FEOBV PET study (2016) (0)
- Pattern of cardiac s ympathetic Denervation in idiopathic Parkinson Disease s tudied with (2012) (0)
- P2-037: Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's disease neuroimaging initiative (2008) (0)
- Nicotine effects on regional cerebral blood flow and glucose in awake resting tobacco smokers (2001) (0)
- In Vivo Mapping of Cholmergic Termina in Normal & ng , Alzheimer ' s Disease , and Parlunson ' s Disease l eri (0)
- TWO-YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI-2 PARTICIPANTS: RELATION TO GENETIC RISK (2014) (0)
- Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration (2020) (0)
- Motor Dysfbnstion in Olivopontoserebellar AtroDhv Is Related to Cerebral Metabolic (1988) (0)
- Interventional studies for validation of non-invasive dual-tracer PET (2006) (0)
- Disrupted functional connectivity in autosomal dominant Alzheimer’s disease demonstrates network specificity and precedes brain volume loss: Findings from the Dominantly Inherited Alzheimer Network (2013) (0)
- A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
- REM sleep behavior disorder is associated with cortical cholinergic deficit in Parkinson's disease without dementia (2010) (0)
- Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography (2011) (0)
- Stereospecificity of in vitro and in vivo binding of isomers of alpha-[C-11]dihydrotetrabenazine alpha -[C-11]DTBZ) to vesicular monoamine transporters. (1995) (0)
- Current BER Scientists: Principal Investigators (2001) (0)
- Application of an Alzheimer's disease hypometabolism index to FDG-PET data from ADNI (2008) (0)
- O1-04-05 Six-month cerebral metabolic declines in Alzheimer’s disease, amnestic mild cognitive impairment and elderly normal control groups: Preliminary findings from the Alzheimer’s disease neuroimaging initiative (2007) (0)
- Spinocerebellar Ataxia Type 1 with-Multiple and Glial System Degeneration n 1 * T 1 . Lytoplasmc lnclusions (2004) (0)
- Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
- PIII‐37 (2006) (0)
- Gantnerumab In-depth Outcomes (2020) (0)
- Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease. (2023) (0)
- Distance weighting for improved tomographic reconstructions (1984) (0)
- Bradykinesia, Rigidity, and Postural Instability and Gait Difficulty Occur More Commonly in Men with Parkinson Disease Compared to Women Independent of Nigrostriatal Dopaminergic Denervation (P06.044) (2012) (0)
- NEURONAL INJURY AND DEGENERATION EVALUATED WITH IMAGING AND CSF BIOMARKERS IN AUTOSOMAL DOMINANT AD: RESULTS FROM THE DIAN STUDY (2016) (0)
- P1-338: The consistency of hypometabolic brain voxels in probable Alzheimer's disease and amnestic mild cognitive impairment patients from the Alzheimer's disease neuroimaging initiative (2008) (0)
- Regional white matter lesions and Pittsburgh compound B retention in cognitively impaired elderly (2013) (0)
- Progressive white matter abnormalities in autosomal-dominant Alzheimer's disease: Results of the DIAN study (2012) (0)
- COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD (2018) (0)
- Reply (1996) (0)
- The role of APOE genotype in early mild cognitive impairment (E-MCI): Preliminary results from ADNI-2 (2012) (0)
- Reply: Cognition and olfaction in Parkinson's disease (2010) (0)
- The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
- Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort (2011) (0)
- Restoration of Brain Cholinergic Synaptic Density by Long-Term Postmenopausal Estrogen Replacement (1998) (0)
- Variability in foot-tapping as a new biomarker of nigrostriatal dopaminergic denervation in Parkinson's disease (2009) (0)
- Cholinergic and dopaminergic PET imaging of gait in Parkinson disease (2010) (0)
- IC-P2-114: Meta-analysis ROIs and minimal deformation templates improve PET-FDG as a candidate biomarker in Alzheimer's disease (2008) (0)
- Cognitive correlates of posterior cingulate hypometabolism in Parkinson disease (2008) (0)
- Peripheral blood plasma protein levels are associated with Pittsburgh compound B binding in the brain (2013) (0)
- More severe parkinsonism is associated with lower physical activity-related energy expenditure in PD (P7.289) (2015) (0)
- Increased white matter MRI T1 hypointensity volume in young‐onset Alzheimer’s disease patients is not accounted for by age or cardiovascular risk factors (2020) (0)
- COMPARINGTHECENTILOIDSCALEFOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD MEMORY ACROSS ALZHEIMER’S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF ATAU PROPAGATION PREDICTED BY BRAAK STAGING (2018) (0)
- H 20 Positron Emission Tomography Determination of Cerebral Blood Flow during Balloon Test Occlusion of the Internal Carotid Artery (2013) (0)
- Peripheral blood plasma protein levels are associated with Pittsburgh compound B-binding in the brain (2013) (0)
- A CONTINUOUSFLOWINPUTFUNCTIONDETECTORFORH2150BLOODFLOWSTUDIESIN POSITRONEMISSIONTOMOGRAPHY (1986) (0)
- P2-282 Quality assurance in a multi-center PET imaging trial (2006) (0)
- Disrupted functional connectivity in autosomal dominant Alzheimer’s disease demonstrates network specificity and precedes brain volume loss: Findings from DIAN (2013) (0)
- NEURONAL INJURY AND DEGENERATION EVALUATED WITH IMAGING AND CSF BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: RESULTS FROM THE DIAN STUDY (2016) (0)
- Striatal dopaminergic correlates of the Montreal Cognitive Assessment test and the Mini Mental State Exam in Parkinson disease: A [11C]-DTBZ PET study (2012) (0)
- 42. Restoration of brain cholinergic synaptic density by long-term postmenopausal estrogen replacement (1998) (0)
- Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer’s Disease Study (LEADS) sample: Results from the MRI core (2020) (0)
- AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains (2022) (0)
- Heterogeneity of neurodegeneration in Parkinson disease: Variable degree of dopaminergic versus cholinergic denervation (2009) (0)
- Diabetes Is Associated with Bradykinesia and Postural Instability and Gait Difficulty in Parkinson Disease Independent of Nigrostriatal Dopaminergic Denervation: A Case-Control Study (P07.125) (2012) (0)
- ADVANCING CLINICAL AND BIOMARKER RESEARCH IN AD: THE LEAD STUDY (2019) (0)
- Cortical and subcortical cholinergic innervation in normal aging (2010) (0)
- Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
- Older age of Parkinson's disease onset associated with increased cognitive impairment, even in patients without dementia (1999) (0)
- Estradiol effects on μ-opioid neurotransmission during stress (2003) (0)
- Posterior cortical hypometabolism precedes mixed subcortical-cortical metabolic changes in incident dementia in Parkinson disease (2008) (0)
- No Dopamine Agonist Modulation of Brain [18F]FEOBV Binding in Parkinson’s Disease (2022) (0)
- Cerebral blood flow activation of the anterior cingulate gyrus studied with positron emission tomography (1993) (0)
- The Study of Schizophrenia via in Vivo S'p and 'h Mrs Long-term Follow-up Study of Frontal Lobotomy in Schizophrenia Cerebral Blood Flow Activation of the Anterior Cingulate Gyrus Studied with Positron Emission Tomography (0)
- The role of APOE-ɛ4 genotype in early mild cognitive impairment (EMCI): Preliminary results from ADNI-2 (2012) (0)
- Striatal and cortical amyloidopathy and cognitive functions in Parkinson disease at risk of dementia (2015) (0)
- Biomarker clustering in autosomal dominant Alzheimer's disease (2022) (0)
- EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2017) (0)
- Lower Education Status Associates With Axial Motor Burden In Parkinson Disease (P5.265) (2014) (0)
- Automated production of [11C]butyrate for keto body PET imaging. (2023) (0)
- Title Large-scale genomics unveil polygenic architecture of human cortical surface area Permalink (2015) (0)
- IC-P2-128: Twelve-month cerebral metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer's disease neuroimaging initiative (2008) (0)
- Measurement of Amino Acid Uptake and Distribution V olume in Human Brain (1990) (0)
- rPOP: Robust PET‐only processing and quantification of community‐acquired amyloid‐PET from the IDEAS Study (2021) (0)
- Cerebellar vermis vesicular acetylcholine transporter expression and parkinsonian motor impairment (2014) (0)
- Letter naming among distracters activates anterior cingulate cortex in a selective attention task (1998) (0)
- Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
- Graded visual activation in schizophrenia (1996) (0)
- Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease (2018) (0)
- P1-312: Differentiating amnestic mild cognitive impairment converting to probable Alzheimer's disease from stable amnestic mild cognitive impairment using FDG-PET and an Alzheimer's disease-related hypometabolism overlap index (2008) (0)
- Regional Serotonin Terminal Density in Aging Human Brain: A [11C]DASB Pet Study (2022) (0)
- UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE POPULATION: REPORT FROM THE DIAN STUDY (2017) (0)
- 358. Cortical function in schizophrenia during blood flow activation (1996) (0)
- Evaluation of the pons as a reference region for amyloid PET in Alzheimer's disease clinical trials (2013) (0)
- 239. Dissociating selective attention and strees in the Stroop interference paradigm (1996) (0)
- Reducing inter-scanner PET image variability (2006) (0)
- O1‐07‐06: Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography (2011) (0)
- The pattern of cerebral hypometabolism and its association with clinical ratings in cognitively normal older adults with and without significant fibrillar amyloid burden: Findings from the Alzheimer's Disease Neuroimaging Initiative (2013) (0)
- Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
- Regional white matter lesions and PIB retention in cognitively impaired elderly (2013) (0)
- 184. CBF activation in post traumatic stress disorder: Spect studies (1996) (0)
- P3-395 A comparison of FDG-PET and neuropsychological testing in differentiating Alzheimer's disease from dementia with lewy bodies (2004) (0)
- Presence and intensity of tremor reflects subcortical cholinergic but not nigrostriatal dopaminergic innervation changes in Parkinson disease (2010) (0)
- PET neurochemical vs. clinical phenotypes in mild-early dementia (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert Allen Koeppe?
Robert Allen Koeppe is affiliated with the following schools:
